Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LON D LYNN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1497898282
CMS profile
204601
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,059.37

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,031.59 57
Education $27.78 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LON D LYNN

NPI 1497898282 · CMS profile ID 204601

Allopathic & Osteopathic Physicians / Family Medicine

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 59 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1497898282?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $1,059.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amneal Pharmaceuticals LLC $13.4812/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667317 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4212/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716532 CMS
Smith+Nephew, Inc. $59.5812/09/2021 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 843159417 CMS
Eisai Inc. $18.5912/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845775529 CMS
AstraZeneca Pharmaceuticals LP $15.0211/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829654089 CMS
AstraZeneca Pharmaceuticals LP $16.3311/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829776629 CMS
Novo Nordisk Inc $24.1711/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094405 CMS
Endo Pharmaceuticals Inc. $16.3210/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828700153 CMS
AstraZeneca Pharmaceuticals LP $13.3710/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829548257 CMS
Merck Sharp & Dohme Corporation $12.9610/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848445245 CMS
Genentech USA, Inc. $14.9910/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835942209 CMS
Abbott Laboratories $18.4510/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815725597 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.0110/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789035181 CMS
AstraZeneca Pharmaceuticals LP $14.0409/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829351817 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.7809/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716534 CMS
Amgen Inc. $13.8909/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534999 CMS
Amneal Pharmaceuticals LLC $11.6709/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667311 CMS
DEXCOM, INC. $16.9209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286859 CMS
Novo Nordisk Inc $19.5209/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811133699 CMS
Abbott Laboratories $22.4608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732605 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.2408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789167369 CMS
Lilly USA, LLC $22.4708/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818660655 CMS
Merck Sharp & Dohme Corporation $14.8308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848467299 CMS
Amgen Inc. $18.2708/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560071 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.6607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763716536 CMS
AstraZeneca Pharmaceuticals LP $13.6007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829901891 CMS
Novo Nordisk Inc $16.4507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810976691 CMS
Novo Nordisk Inc $2.5206/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897871 CMS
Novo Nordisk Inc $19.1306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810897879 CMS
AstraZeneca Pharmaceuticals LP $14.6006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829897633 CMS
AstraZeneca Pharmaceuticals LP $12.1806/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829938303 CMS
SANOFI-AVENTIS U.S. LLC $20.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408675 CMS
AstraZeneca Pharmaceuticals LP $13.9506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829329589 CMS
AstraZeneca Pharmaceuticals LP $12.4006/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829395613 CMS
Amgen Inc. $14.8506/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560067 CMS
DEXCOM, INC. $18.4205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845286857 CMS
Novo Nordisk Inc $24.1105/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810937589 CMS
Lilly USA, LLC $11.5505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818596861 CMS
Merck Sharp & Dohme Corporation $11.2004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848597345 CMS
Amneal Pharmaceuticals LLC $18.7804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829667307 CMS
AstraZeneca Pharmaceuticals LP $16.5204/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830073867 CMS
Novo Nordisk Inc $17.5704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811094399 CMS
SANOFI-AVENTIS U.S. LLC $20.9804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408643 CMS
Amgen Inc. $13.5004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825560063 CMS
Amgen Inc. $13.8904/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826534997 CMS
Novo Nordisk Inc $20.2203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811173081 CMS
SANOFI-AVENTIS U.S. LLC $16.8603/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843408607 CMS
Radius Health, Inc. $23.2803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830727017 CMS
AstraZeneca Pharmaceuticals LP $13.1802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829485817 CMS
AstraZeneca Pharmaceuticals LP $13.6802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829984441 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,623.35 59
PY2020 $4,240.58 60
PY2021 $1,059.37 59
PY2022 $317.77 13
PY2023 $770.34 4
PY2024 $2,741.69 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,774,310.43 131
PY2024 Recipient $1,401.65 10
PY2024 Principal investigator $1,886,016.65 154
PY2023 Recipient $1,734.07 2
PY2023 Principal investigator $1,613,093.87 174
PY2022 Recipient $7,938.00 2
PY2022 Principal investigator $1,203,947.96 117
PY2021 Recipient $1,793.52 3
PY2021 Principal investigator $874,519.06 78
PY2020 Principal investigator $706,623.45 80
PY2019 Recipient $1,208.55 9
PY2019 Principal investigator $596,855.42 115

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,538.02 12/31/2019 Non-covered Recipient Entity
Clinical Research Of West Florida
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684977825
Principal investigator 1 AbbVie, Inc. $10,685.30 12/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590769
Principal investigator 1 AbbVie, Inc. $1,772.35 12/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840857
Principal investigator 1 Novo Nordisk AS $6,138.10 12/19/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452839
Principal investigator 1 Novo Nordisk AS $75.00 12/12/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674533
Principal investigator 1 Novo Nordisk AS $70.86 12/12/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674535
Principal investigator 1 SANOFI US SERVICES INC. $1,058.27 12/11/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598665
Principal investigator 1 AbbVie, Inc. $6,941.95 12/05/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590771
Principal investigator 1 Novo Nordisk AS $5,112.66 12/03/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452837
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,415.40 12/01/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Tampa
Tio & Olo versus PBO stratified by PIFR No dispute reported 06/30/2026 749644399
Principal investigator 1 SANOFI US SERVICES INC. $873.33 11/25/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691597712
Principal investigator 1 SANOFI US SERVICES INC. $1,012.68 11/13/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691598575
Principal investigator 1 SANOFI US SERVICES INC. $682.88 11/13/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691599577
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $21.76 11/06/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090439
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 11/06/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090443
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 11/06/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090445
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 11/06/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090447
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 11/06/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090449
Principal investigator 1 SANOFI US SERVICES INC. $1,657.73 11/04/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691595487
Principal investigator 1 AbbVie, Inc. $31.05 10/31/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840851
Principal investigator 1 AbbVie, Inc. $11,842.65 10/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590761
Principal investigator 1 Beckman Coulter, Inc. $58,656.00 10/29/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA INCORPORATED
BNPNTproBNP No dispute reported 06/30/2026 704729743
Principal investigator 1 Novo Nordisk AS $3,535.33 10/29/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452829
Principal investigator 1 AbbVie, Inc. $3,000.00 10/28/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590767
Principal investigator 1 AbbVie, Inc. $2,000.00 10/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590763
Principal investigator 1 AbbVie, Inc. $7,100.10 10/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590765
Principal investigator 1 SANOFI US SERVICES INC. $299.73 10/21/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691594831
Principal investigator 1 AbbVie, Inc. $10,000.00 10/07/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840855
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.50 10/07/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090391
Principal investigator 1 AbbVie, Inc. $9,786.85 10/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840853
Principal investigator 1 AbbVie, Inc. $23,634.35 09/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590757
Principal investigator 1 Novo Nordisk AS $4,090.12 09/26/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452835
Principal investigator 1 AbbVie, Inc. $15,548.35 09/12/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590759
Principal investigator 1 SANOFI US SERVICES INC. $6,560.11 09/09/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691588115
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $31.73 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090083
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32.25 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090085
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090087
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.60 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090091
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090093
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.88 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090097
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.78 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090101
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.90 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090117
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $43.52 09/04/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686090121
Principal investigator 1 Novo Nordisk AS $4,121.34 08/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452833
Principal investigator 1 AbbVie, Inc. $6,000.00 08/29/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840847
Principal investigator 1 AbbVie, Inc. $4,350.00 08/28/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-431 No dispute reported 06/30/2026 671840845
Principal investigator 1 AbbVie, Inc. $3,000.00 08/20/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M15-991 No dispute reported 06/30/2026 671840849
Principal investigator 1 Novo Nordisk AS $17.07 08/13/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674531
Principal investigator 1 Novo Nordisk AS $22.12 08/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674527
Principal investigator 1 SANOFI US SERVICES INC. $2,480.00 08/05/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691583515
Principal investigator 1 AbbVie, Inc. $7,086.50 08/01/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590785
Principal investigator 1 Novo Nordisk AS $49,222.26 07/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452811
Principal investigator 1 Novo Nordisk AS $500.00 07/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452813
Principal investigator 1 Novo Nordisk AS $1,000.00 07/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452815
Principal investigator 1 Novo Nordisk AS $7,177.61 07/30/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452831
Principal investigator 1 SANOFI US SERVICES INC. $299.73 07/25/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691581655
Principal investigator 1 Novo Nordisk AS $144.09 07/17/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674525
Principal investigator 1 AbbVie, Inc. $1,550.00 07/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590781
Principal investigator 1 AbbVie, Inc. $4,243.75 07/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590783
Principal investigator 1 Novo Nordisk AS $2,468.55 06/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452827
Principal investigator 1 Novo Nordisk AS $126.00 06/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674521
Principal investigator 1 SANOFI US SERVICES INC. $1,636.39 06/24/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function No dispute reported 06/30/2026 691606229
Principal investigator 1 Janssen Research & Development, LLC $2,560.00 06/18/2019 Non-covered Recipient Entity
Clnc Rsrch Of W Fl
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654246847
Principal investigator 1 SANOFI US SERVICES INC. $510.22 06/10/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691582943
Principal investigator 1 Novo Nordisk AS $5,586.66 05/28/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452825
Principal investigator 1 AbbVie, Inc. $15,050.35 05/20/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590779
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $54.40 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089621
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $21.76 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089623
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $21.76 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089625
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $31.73 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089627
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5.00 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089629
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $25.80 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089631
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.30 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089633
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $121.88 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089635
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.45 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089637
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.78 05/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH(W)FL
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF JZP-258 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) WITH AN OPEN-LABEL SAFETY EXTENSION No dispute reported 06/30/2026 686089639
Principal investigator 1 AbbVie, Inc. $3,000.00 04/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590775
Principal investigator 1 Novo Nordisk AS $6,879.94 04/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452823
Principal investigator 1 Novo Nordisk AS $93.73 04/23/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674515
Principal investigator 1 Janssen Research & Development, LLC $2,329.00 04/22/2019 Non-covered Recipient Entity
Clnc Rsrch Of W Fl
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654246817
Principal investigator 1 SANOFI US SERVICES INC. $3,217.49 04/22/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691574771
Principal investigator 1 SANOFI US SERVICES INC. $2,181.53 04/22/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691574955
Recipient GlaxoSmithKline, LLC. $517.73 04/10/2019 Covered Recipient Physician A 24 MONTH DOUBLE BLIND RANDOMISED PARALLEL GROUP STUDY TO DETERMINE T No dispute reported 06/30/2026 669961135
Recipient GlaxoSmithKline, LLC. $56.27 04/10/2019 Covered Recipient Physician A 24 MONTH DOUBLE BLIND RANDOMISED PARALLEL GROUP STUDY TO DETERMINE T No dispute reported 06/30/2026 669961647
Principal investigator 1 Janssen Research & Development, LLC $6,900.00 04/04/2019 Non-covered Recipient Entity
Clnc Rsrch Of W Fl
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 654246845
Principal investigator 1 AbbVie, Inc. $7,528.55 04/03/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590777
Principal investigator 1 SANOFI US SERVICES INC. $3,507.52 04/01/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691573763
Principal investigator 1 Novo Nordisk AS $540.00 03/26/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452807
Principal investigator 1 Novo Nordisk AS $453.00 03/26/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452809
Principal investigator 1 Novo Nordisk AS $6,796.87 03/26/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452821
Principal investigator 1 AbbVie, Inc. $300.00 03/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M15-991 No dispute reported 06/30/2026 671840859
Principal investigator 1 AbbVie, Inc. $435.00 03/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-433 No dispute reported 06/30/2026 671840861
Principal investigator 1 AbbVie, Inc. $435.00 03/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-431 No dispute reported 06/30/2026 671840863
Principal investigator 1 AbbVie, Inc. $300.00 03/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840865
Recipient GlaxoSmithKline, LLC. $244.61 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669958509
Recipient GlaxoSmithKline, LLC. $61.40 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669959311
Recipient GlaxoSmithKline, LLC. $23.78 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669960151
Recipient GlaxoSmithKline, LLC. $54.40 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669960513
Recipient GlaxoSmithKline, LLC. $30.04 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669960541
Recipient GlaxoSmithKline, LLC. $190.28 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669961269
Recipient GlaxoSmithKline, LLC. $30.04 03/14/2019 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 669974663
Principal investigator 1 Novo Nordisk AS $167.51 03/14/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674511
Principal investigator 1 Novo Nordisk AS $7.11 03/14/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 706674513
Principal investigator 1 Novo Nordisk AS $2,330.40 02/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452801
Principal investigator 1 Novo Nordisk AS $712.39 02/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452803
Principal investigator 1 Novo Nordisk AS $1,099.18 02/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452805
Principal investigator 1 Novo Nordisk AS $7,972.32 02/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452819
Principal investigator 1 AbbVie, Inc. $2,000.00 02/19/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M18-891 No dispute reported 06/30/2026 647590773
Principal investigator 1 SANOFI US SERVICES INC. $9,439.07 02/18/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691563755
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,004.90 01/29/2019 Non-covered Recipient Entity
Clinical Research Of West
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease No dispute reported 06/30/2026 639758703
Principal investigator 1 AbbVie, Inc. $14,000.00 01/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-000 No dispute reported 06/30/2026 671840867
Principal investigator 1 AbbVie, Inc. $14,000.00 01/25/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M16-006 No dispute reported 06/30/2026 671840877
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,383.69 01/24/2019 Non-covered Recipient Entity
Clinical Research Of West Florida
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 684977817
Principal investigator 1 Novo Nordisk AS $12,782.98 01/24/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN1250-4252 No dispute reported 06/30/2026 692452799
Principal investigator 1 Novo Nordisk AS $10,284.77 01/24/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
NN9536-4374 No dispute reported 06/30/2026 692452817
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,060.80 01/22/2019 Non-covered Recipient Entity
Clinical Research Of West Florida
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 684977813
Principal investigator 1 SANOFI US SERVICES INC. $2,181.53 01/14/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691559977
Principal investigator 1 SANOFI US SERVICES INC. $4,918.87 01/14/2019 Non-covered Recipient Entity
Clinical Research Of West Florida Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardi No dispute reported 06/30/2026 691563069
Principal investigator 1 AbbVie, Inc. $14,000.00 01/09/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M15-991 No dispute reported 06/30/2026 671840869
Principal investigator 1 AbbVie, Inc. $15,000.00 01/09/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-430 No dispute reported 06/30/2026 671840871
Principal investigator 1 AbbVie, Inc. $15,000.00 01/09/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-433 No dispute reported 06/30/2026 671840873
Principal investigator 1 AbbVie, Inc. $15,000.00 01/09/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
M14-431 No dispute reported 06/30/2026 671840875
Principal investigator 1 Mylan Specialty L.P. $11,535.40 01/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA, INC.
Research_A Phase 3b, 28-day, Randomized, Active-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin administered before Nebulized Formoterol Fumarate (PER No dispute reported 06/30/2026 679290998
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,250.00 01/01/2019 Non-covered Recipient Entity
CLINICAL RESEARCH OF WEST FLORIDA
AN OPEN LABEL SINGLE ARM MULTI CENTER EXTENSION STUDY EVALUATING LONG TERM SAFETY TOLERABILITY AND EFFECTIVENESS OF OFATUMUMAB IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 640713919